Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients
Viruses · 28.05.2024 · 16 (6) · 864
DOI: 10.3390/v16060864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 28.05.2024. Verfasst von Nadia Exquis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, Geneva Universi…. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment, Alanine, Adenosine Monophosphate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1)
Background
Geriatric patients are at high risk of complications of Coronavirus disease-2019 (COVID-19) and are good candidates for antiviral drugs. (2)
Methods
A retrospective study of electronic health records (EHRs) aiming to describe antiviral (nirmatrelvir and ritonavir (nirmatrelvir/r) or remdesivir) use, drug–drug interactions (DDIs) and adverse drug reactions (ADRs) in elderly patients (75 and over), hospitalized with mild-to-moderate COVID-19 between July 2022 and June 2023. (3)
Results
Out of 491 patients (mean age: 86.9 years), 180 (36.7%) received nirmatrelvir/r, 78 (15.9%) received remdesivir, and 233 (47.4%) received no antiviral therapy. No association was found between the choice of antiviral and the demographic or medical data. No serious ADR was observed. Nirmatrelvir/r dosage adjustment was inadequate in 65% of patients with renal impairment. In total, 128 patients (71%) on nirmatrelvir/r had potential pharmacokinetic DDIs, with 43 resulting in a possibly related ADR. In the remdesivir group, pharmacodynamic DDIs were more frequent, with QTc prolongation risk in 56 patients (72%). Only 20 patients underwent follow-up ECG, revealing QTc prolongation in 4. (4)
Conclusions
There is an underutilization of antivirals despite their justified indications. Nirmatrelvir/r dosage was rarely adjusted to renal function. Dose adjustments and closer monitoring are needed due to the high risk of drug interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.
- Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland.
- Division of Internal Medicine for the Aged, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, 1205 Geneva, Switzerland.
- Division of Geriatrics and Rehabilitation, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, 1205 Geneva, Switzerland.
- Division of Infectious Disease, Geneva University Hospitals, 1205 Geneva, Switzerland.
ORCID-Profile: Christophe Graf, Kuntheavy Ing Lorenzini
Zitieren
APA
Exquis, N., Dionisi, B., Samer, C. F., Rollason, V., Curtin, F., Zekry, D., Graf, C., Prendki, V., & Ing Lorenzini, K. (2024). Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients. Viruses, 16(6), 864. https://doi.org/10.3390/v16060864
Vancouver
Exquis N, Dionisi B, Samer CF, Rollason V, Curtin F, Zekry D, et al. Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients. Viruses. 2024;16(6):864. doi:10.3390/v16060864
BibTeX
@article{Exquis2024,
author = {Exquis, Nadia and Dionisi, Benjamin and Samer, Caroline Flora and Rollason, Victoria and Curtin, François and Zekry, Dina and Graf, Christophe and Prendki, Virgnie and Ing Lorenzini, Kuntheavy},
title = {Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients},
journal = {Viruses},
year = {2024},
volume = {16},
number = {6},
pages = {864},
doi = {10.3390/v16060864}
}
EUVIMED